	US 12,448,452 B2
	Methods and compositions relating to anti-PD1 antibody reagents
Frederick W. Alt, Cambridge, MA (US); Ming Tian, Boston, MA (US); and Hwei-Ling Cheng, Northborough, MA (US)
Assigned to THE CHILDREN'S MEDICAL CENTER CORPORATION, Boston, MA (US)
Filed by THE CHILDREN'S MEDICAL CENTER CORPORATION, Boston, MA (US)
Filed on Jul. 21, 2022, as Appl. No. 17/870,010.
Application 17/870,010 is a division of application No. 16/608,275, granted, now 11,427,636, previously published as PCT/US2018/030350, filed on May 1, 2018.
Claims priority of provisional application 62/492,533, filed on May 1, 2017.
Prior Publication US 2023/0192855 A1, Jun. 22, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); C07K 16/28 (2006.01); A61K 35/17 (2015.01)

CPC C07K 16/2818 (2013.01) [A61K 39/001111 (2018.08); C07K 16/2803 (2013.01); A61K 35/17 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01)]

15 Claims

1. A nucleic acid sequence encoding an antibody, antibody reagent, antigen-binding fragment thereof, or chimaeric antigen receptor (CAR), that specifically binds an PD1 polypeptide, said antibody reagent, antigen-binding portion thereof, or CAR comprising:

heavy chain complementarity determining regions (CDRs) having the amino acid sequences of SEQ ID NOs: 23-25 and light chain CDRs having the amino acid sequences of SEQ ID NO: 26, DAS and SEQ ID NO: 28; or

heavy chain CDRs having the amino acid sequences of SEQ ID NOs: 29-31 and light chain CDRs having the amino acid sequences of SEQ ID NO: 32, DAS and SEQ ID NO: 34; or

heavy chain CDRs having the amino acid sequences of SEQ ID NOs: 35-37 and light chain CDRs having the amino acid sequences of SEQ ID NO: 38, DAS and SEQ ID NO: 40; or

heavy chain CDRs having the amino acid sequences of SEQ ID NOs: 41-43 and light chain CDRs having the amino acid sequences of SEQ ID NO: 44, DAF and SEQ ID NO:46; or

heavy chain CDRs having the amino acid sequences of SEQ ID NOs: 47-49 and light chain CDRs having the amino acid sequences of SEQ ID NO: 50, DAS and SEQ ID NO: 52; or

heavy chain CDRs having the amino acid sequences of SEQ ID NOs: 53-55 and light chain CDRs having the amino acid sequences of SEQ ID NO: 56, GAS and SEQ ID NO: 58; or

heavy chain CDRs having the amino acid sequences of SEQ ID NOs: 59-61 and light chain CDRs having the amino acid sequences of SEQ ID NO: 62, DAS and SEQ ID NO: 64; or

heavy chain CDRs having the amino acid sequences of SEQ ID NOs: 65-67 and light chain CDRs having the amino acid sequences of SEQ ID NO: 68, DAS and SEQ ID NO: 70; or

heavy chain CDRs having the amino acid sequences of SEQ ID NOs: 71-73 and light chain CDRs having the amino acid sequences of SEQ ID NO: 74, DAS and SEQ ID NO: 76; or

heavy chain CDRs having the amino acid sequences of SEQ ID NOs: 77-79 and light chain CDRs having the amino acid sequences of SEQ ID NO: 80, DAS and SEQ ID NO: 82; or

heavy chain CDRs having the amino acid sequences of SEQ ID NOs: 83-85 and light chain CDRs having the amino acid sequences of SEQ ID NO: 86, DAS and SEQ ID NO: 88.